Jim Simons Gt Biopharma, Inc. Transaction History

Renaissance Technologies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.22 - $0.28 $10,558 - $13,438	47,995 Added 71.96%	114,695 $29,000
Q3 2023 Nov 14, 2023	SELL	$0.24 - $0.35 $6,115 - $8,918	-25,481 Reduced 27.64%	66,700 $16,000
Q2 2023 Aug 11, 2023	BUY	$0.22 - $0.55 $5,011 - $12,529	22,781 Added 32.83%	92,181 $29,000
Q1 2023 May 12, 2023	BUY	$0.46 - $1.05 $10,672 - $24,360	23,200 Added 50.22%	69,400 $38,000
Q4 2022 Feb 13, 2023	BUY	$0.89 - $58.2 $41,118 - $2.69 Million	46,200 New	46,200 $41,000
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.11 $199,422 - $378,172	-121,599 Reduced 65.27%	64,701 $193,000
Q1 2022 May 13, 2022	SELL	$2.6 - $3.3 $313,040 - $397,320	-120,400 Reduced 39.26%	186,300 $537,000
Q4 2021 Feb 11, 2022	BUY	$3.05 - $7.08 $677,100 - $1.57 Million	222,000 Added 262.1%	306,700 $935,000
Q3 2021 Nov 12, 2021	BUY	$6.68 - $15.26 $565,796 - $1.29 Million	84,700 New	84,700 $571,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.